Biohaven's study miss triggers share drop; future focus on alternative therapies

25 days ago

Bloomberg's Isabel Lee

"Biohaven shares drop 14%. um they're in the healthcare industry. So shares are slumping because um a mid-stage study of the company's experimental drug for the treatment of major depressive disorder missed the primary endpoint. So City said the data was disappointing. They had a buy rating, but investors had quote very low expectations of the study working. Raymon James, who also had a buy rating, said that investors should stay focused on the focal epilepsy opportunity. And RBC said that the trial miss could be a clearing event, so to speak."

The speaker explains that Biohaven (BHVN) experienced a sharp 14% drop in shares after its experimental drug missed a primary endpoint. Despite previous buy ratings, the market's low expectations suggest that the company may shift its focus to other therapeutic areas like epilepsy, reflecting immediate investor concerns.

Related Stocks